Gsk (GSK) Income from Continuing Operations (2009 - 2026)

Gsk's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 207960167.13 for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 92.67% year-over-year to 207960167.13; the TTM figure through Jun 2026 stood at 14037842267.93 (up 35.87% YoY), while the FY2025 annual figure was 8292111502.56, up 119.82% from the prior year.
• Income from Continuing Operations for Q2 2026 stood at 207960167.13, down from 3301688900.49 in the prior quarter.
• The five-year high for Income from Continuing Operations was 6793158775.57 in Q4 2025, with the low at 81855910.5 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 2814068842.45 (2023), against an average of 2853923369.74.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 96.84% in 2024, then jumped 4462.94% in 2025.
• Gsk's Income from Continuing Operations stood at 4336316003.25 in 2022, then surged by 33.09% to 5771356267.04 in 2023, then slipped by 24.92% to 4333102209.79 in 2024, then surged by 56.77% to 6793158775.57 in 2025, then slumped by 96.94% to 207960167.13 in 2026.
• Business Quant data shows GSK's Income from Continuing Operations at 207960167.13 in Q2 2026, 3301688900.49 in Q1 2026, and 6793158775.57 in Q4 2025.